Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Research Articles: Therapeutics, Targets, and Development

  • Research Articles: Therapeutics, Targets, and Development
    Inhibition of Src family kinases enhances retinoic acid–induced gene expression and myeloid differentiation
    Michelle B. Miranda, Robert L. Redner and Daniel E. Johnson
    Mol Cancer Ther December 1 2007 6 (12) 3081-3090; DOI:10.1158/1535-7163.MCT-07-0514

  • Research Articles: Therapeutics, Targets, and Development
    In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches
    Bianca Maria Veneziani, Vittoria Criniti, Carla Cavaliere, Sara Corvigno, Agostina Nardone, Silvia Picarelli, Giampaolo Tortora, Fortunato Ciardiello, Gennaro Limite and Sabino De Placido
    Mol Cancer Ther December 1 2007 6 (12) 3091-3100; DOI:10.1158/1535-7163.MCT-07-0356

  • Research Articles: Therapeutics, Targets, and Development
    Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells
    Clint Mitchell, Maragret A. Park, Guo Zhang, Adly Yacoub, David T. Curiel, Paul B. Fisher, John D. Roberts, Steven Grant and Paul Dent
    Mol Cancer Ther December 1 2007 6 (12) 3101-3112; DOI:10.1158/1535-7163.MCT-07-0561

  • Research Articles: Therapeutics, Targets, and Development
    Inactivation of glycogen synthase kinase-3β contributes to brain-derived neutrophic factor/TrkB-induced resistance to chemotherapy in neuroblastoma cells
    Zhijie Li, Fei Tan and Carol J. Thiele
    Mol Cancer Ther December 1 2007 6 (12) 3113-3121; DOI:10.1158/1535-7163.MCT-07-0133

  • Research Articles: Therapeutics, Targets, and Development
    Chemical synthesis and biological evaluation of a NAD(P)H:quinone oxidoreductase-1–targeted tripartite quinone drug delivery system
    Milène Volpato, Nathalie Abou-Zeid, Richard W. Tanner, Lee T. Glassbrook, James Taylor, Ian Stratford, Paul M. Loadman, Mohammed Jaffar and Roger M. Phillips
    Mol Cancer Ther December 1 2007 6 (12) 3122-3130; DOI:10.1158/1535-7163.MCT-07-0519

  • Research Articles: Therapeutics, Targets, and Development
    Antineoplastic agents target the 25-hydroxyvitamin D3 24-hydroxylase messenger RNA for degradation: implications in anticancer activity
    Joseph Tan, Prem P. Dwivedi, Paul Anderson, Barbara K. Nutchey, Peter O'Loughlin, Howard A. Morris, Brian K. May, Antonio Ferrante and Charles S. Hii
    Mol Cancer Ther December 1 2007 6 (12) 3131-3138; DOI:10.1158/1535-7163.MCT-07-0427

  • Research Articles: Therapeutics, Targets, and Development
    The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent
    Nicola Vannini, Girieca Lorusso, Rosaria Cammarota, Massimo Barberis, Douglas M. Noonan, Michael B. Sporn and Adriana Albini
    Mol Cancer Ther December 1 2007 6 (12) 3139-3146; DOI:10.1158/1535-7163.MCT-07-0451

  • Research Articles: Therapeutics, Targets, and Development
    Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity
    Florence Chan, Chongbo Sun, Meg Perumal, Quang-De Nguyen, Vassilios Bavetsias, Edward McDonald, Vanessa Martins, Nicola E. Wilsher, Florence I. Raynaud, Melanie Valenti, Sue Eccles, Robert te Poele, Paul Workman, Eric O. Aboagye and Spiros Linardopoulos
    Mol Cancer Ther December 1 2007 6 (12) 3147-3157; DOI:10.1158/1535-7163.MCT-07-2156

  • Research Articles: Therapeutics, Targets, and Development
    PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
    Patrizia Carpinelli, Roberta Ceruti, Maria Laura Giorgini, Paolo Cappella, Laura Gianellini, Valter Croci, Anna Degrassi, Gemma Texido, Maurizio Rocchetti, Paola Vianello, Luisa Rusconi, Paola Storici, Paola Zugnoni, Claudio Arrigoni, Chiara Soncini, Cristina Alli, Veronica Patton, Aurelio Marsiglio, Dario Ballinari, Enrico Pesenti, Daniele Fancelli and Jürgen Moll
    Mol Cancer Ther December 1 2007 6 (12) 3158-3168; DOI:10.1158/1535-7163.MCT-07-0444

  • Research Articles: Therapeutics, Targets, and Development
    The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells
    Janna Krol, Richard E. Francis, André Albergaria, Andrew Sunters, Andreas Polychronis, R. Charles Coombes and Eric W.-F. Lam
    Mol Cancer Ther December 1 2007 6 (12) 3169-3179; DOI:10.1158/1535-7163.MCT-07-0507

  • Research Articles: Therapeutics, Targets, and Development
    Chemosensitization of head and neck cancer cells by PUMA
    Quanhong Sun, Tsukasa Sakaida, Wen Yue, Susanne M. Gollin and Jian Yu
    Mol Cancer Ther December 1 2007 6 (12) 3180-3188; DOI:10.1158/1535-7163.MCT-07-0265

  • Research Articles: Therapeutics, Targets, and Development
    Cell type–dependent effects of Polo-like kinase 1 inhibition compared with targeted polo box interference in cancer cell lines
    Jenny Fink, Karl Sanders, Alexandra Rippl, Sylvia Finkernagel, Thomas L. Beckers and Mathias Schmidt
    Mol Cancer Ther December 1 2007 6 (12) 3189-3197; DOI:10.1158/1535-7163.MCT-07-0048

  • Research Articles: Therapeutics, Targets, and Development
    TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth
    Leo Christopher DeRosier, Selwyn M. Vickers, Kurt R. Zinn, Zhi Huang, Wenquan Wang, William E. Grizzle, Jeffrey Sellers, Cecil R. Stockard Jr., Tong Zhou, Patsy G. Oliver, Pablo Arnoletti, Albert F. LoBuglio and Donald J. Buchsbaum
    Mol Cancer Ther December 1 2007 6 (12) 3198-3207; DOI:10.1158/1535-7163.MCT-07-0299

  • Research Articles: Therapeutics, Targets, and Development
    A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor–expressing tumor cells
    Jill Wykosky, Denise M. Gibo and Waldemar Debinski
    Mol Cancer Ther December 1 2007 6 (12) 3208-3218; DOI:10.1158/1535-7163.MCT-07-0200

  • Research Articles: Therapeutics, Targets, and Development
    Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis
    Rachel M. Locklin, Ermanno Federici, Belen Espina, Philippa A. Hulley, R. Graham G. Russell and Claire M. Edwards
    Mol Cancer Ther December 1 2007 6 (12) 3219-3228; DOI:10.1158/1535-7163.MCT-07-0275

  • Research Articles: Therapeutics, Targets, and Development
    Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters
    Kazutaka Takagi, Thomas S. Dexheimer, Christophe Redon, Olivier Sordet, Keli Agama, Gilbert Lavielle, Alain Pierré, Susan E. Bates and Yves Pommier
    Mol Cancer Ther December 1 2007 6 (12) 3229-3238; DOI:10.1158/1535-7163.MCT-07-0441

  • Research Articles: Therapeutics, Targets, and Development
    Efficacy and tissue distribution of DHP107, an oral paclitaxel formulation
    Jung Wan Hong, In-Hyun Lee, Young Hak Kwak, Young Taek Park, Ha Chin Sung, Ick Chan Kwon and Hesson Chung
    Mol Cancer Ther December 1 2007 6 (12) 3239-3247; DOI:10.1158/1535-7163.MCT-07-0261

  • Research Articles: Therapeutics, Targets, and Development
    Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl) nitrosamine–induced urinary bladder carcinogenesis in male ICR mice
    Alpna Tyagi, Komal Raina, Rana P. Singh, Mallikarjuna Gu, Chapla Agarwal, Gail Harrison, L. Michael Glode and Rajesh Agarwal
    Mol Cancer Ther December 1 2007 6 (12) 3248-3255; DOI:10.1158/1535-7163.MCT-07-2006

  • Research Articles: Therapeutics, Targets, and Development
    Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma
    Claudio Scavelli, Giulia Di Pietro, Teresa Cirulli, Mauro Coluccia, Angela Boccarelli, Teresa Giannini, Giuseppe Mangialardi, Raffaello Bertieri, Addolorata Maria Luce Coluccia, Domenico Ribatti, Franco Dammacco and Angelo Vacca
    Mol Cancer Ther December 1 2007 6 (12) 3256-3262; DOI:10.1158/1535-7163.MCT-07-0311

  • Research Articles: Therapeutics, Targets, and Development
    Zoledronic acid inhibits osteosarcoma growth in an orthotopic model
    Crispin R. Dass and Peter F.M. Choong
    Mol Cancer Ther December 1 2007 6 (12) 3263-3270; DOI:10.1158/1535-7163.MCT-07-0546

  • Research Articles: Therapeutics, Targets, and Development
    New inhibitors of ABCG2 identified by high-throughput screening
    Curtis J. Henrich, Robert W. Robey, Heidi R. Bokesch, Susan E. Bates, Suneet Shukla, Suresh V. Ambudkar, Michael Dean and James B. McMahon
    Mol Cancer Ther December 1 2007 6 (12) 3271-3278; DOI:10.1158/1535-7163.MCT-07-0352

  • Research Articles: Therapeutics, Targets, and Development
    The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance–linked ATP binding cassette drug transporter ABCG2
    Suneet Shukla, Chung-Pu Wu, Krishnamachary Nandigama and Suresh V. Ambudkar
    Mol Cancer Ther December 1 2007 6 (12) 3279-3286; DOI:10.1158/1535-7163.MCT-07-0564

  • Research Articles: Therapeutics, Targets, and Development
    Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance–linked ABCG2 transporter
    Chung-Pu Wu, Suneet Shukla, Anna Maria Calcagno, Matthew D. Hall, Michael M. Gottesman and Suresh V. Ambudkar
    Mol Cancer Ther December 1 2007 6 (12) 3287-3296; DOI:10.1158/1535-7163.MCT-07-2005

  • Research Articles: Therapeutics, Targets, and Development
    Kallikrein-binding protein inhibits growth of gastric carcinoma by reducing vascular endothelial growth factor production and angiogenesis
    Baohe Zhu, Lei Lu, Weibin Cai, Xia Yang, Chaoyang Li, Zhonghan Yang, Wenhua Zhan, Jian-xing Ma and Guoquan Gao
    Mol Cancer Ther December 1 2007 6 (12) 3297-3306; DOI:10.1158/1535-7163.MCT-06-0798

  • Research Articles: Therapeutics, Targets, and Development
    In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2
    Serena Marchetti, Roos L. Oostendorp, Dick Pluim, Monique van Eijndhoven, Olaf van Tellingen, Alfred H. Schinkel, Richard Versace, Jos H. Beijnen, Roberto Mazzanti and Jan H. Schellens
    Mol Cancer Ther December 1 2007 6 (12) 3307-3313; DOI:10.1158/1535-7163.MCT-07-0461

  • Research Articles: Therapeutics, Targets, and Development
    Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
    James G. Christensen, Helen Y. Zou, Maria E. Arango, Qiuhua Li, Joseph H. Lee, Scott R. McDonnell, Shinji Yamazaki, Gordon R. Alton, Barbara Mroczkowski and Gerrit Los
    Mol Cancer Ther December 1 2007 6 (12) 3314-3322; DOI:10.1158/1535-7163.MCT-07-0365

  • Research Articles: Therapeutics, Targets, and Development
    Mol Cancer Ther December 1 2007 6 (12) 3323-3329; DOI:10.1158/1535-7163.MCT-6-12-ACK

Back to top
PreviousNext
Molecular Cancer Therapeutics: 6 (12)
December 2007
Volume 6, Issue 12
  • Table of Contents
  • About the Cover

Sign up for alerts

Issue Highlights

  • Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity

Jump to

  • Research Articles: Therapeutics, Targets, and Development
Advertisement
  • Most Cited
  • Most Read
Loading
  • Anti-KIT DNA Aptamer Labeling in GIST
  • SLFN11 Expression in Prostate Cancer
  • Single-cell RNA-seq to Uncover Metastatic Targets in PDAC
  • Tipifarnib as a Precision Therapy for HRAS-Mutant HNSCC
  • ARX788 Efficacy in HER2-low and T-DM1–resistant Cancers
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement